Prefrontal Oscillations in Social Anxiety Disorder (POSAD)
Key facts
- Who runs it
- Institut National de la Santé Et de la Recherche Médicale, France
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 12 Nov 2019
- Ended
- 9 May 2026
- Type of study
- Interventional, 3 groups
- Treatments tested
- In vivo social exposure
- Social exposure in a virtual reality setting
- EEG recording
- Psychometric evaluation
- Visual Analogue Scale of anxiety
- Record updated
- 7 July 2026
Who can take part
- Age
- 20 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Social anxiety disorder as defined in DSM-5
- Full understanding of the protocol
- Obtaining informed consent from study subjects before or at inclusion at the latest
- Being registered in the french national health insurance service (Sécurité Sociale) (or equivalent)
Who cannot take part
- initiation of a psychotropic treatment or change in the dose of ongoing psychotropic treatment within 3 days prior to each visit and including:; antidepressant treatments with selective serotonin recapture inhibitors, serotonin and norepinephrine inhibitors, alpha2-presynaptic adrenoreceptors (mirtazapine, mianserin), tricyclic; anxiolytic drugs including benzodiazepines and anti-histamine; antipsychotic drugs
- Acute alcohol intake 2 days prior to each visit (inclusion, experimental sessions)
- Active medical co-morbidity including severe hypertension, cardiac insufficiency, Raynaud syndrome, diabetes mellitus, renal insufficiency, adrenal insufficiency, Cushing syndrome and epilepsy
- Severe neurological co-morbidity, including but not limited to Parkinson's disease and multiple sclerosis
- History of significant head injury, defined by loss of consciousness
- Being diagnosed with another major psychiatric condition (DSM5) including bipolar disorder and schizophrenia or substance/alcohol use disorder; with the exception of major depressive disorder and nicotine use disorder
- Long-term corticotherapy
- Suicidal risk evaluated as moderate to high in the MINI questionnaire
- Pregnancy or breastfeeding
- Ongoing hospitalization without consent (decision of a third-party: medical, justice)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Experimental fear in rodents is correlated with slow oscillations in electrical recordings of prefrontal cortex activities. The present study aims to test whether slow prefrontal oscillations is a biomarker of pathological anxiety in human subjects.
The 3 groups in the trial
- Group 1: Go-no-go phaseTreatment being tested
The presence of significant prefrontal oscillations in the EEG recording 2-6Hz band during in vivo social exposure (oral presentation to examiners) will be assessed in 10 subjects with social anxiety disorder. EEG will be recorded immediately before, during and after oral presentations to examiners. Psychometric evaluation will be performed prior to experimental sessions. Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods (wainting, presentation, recovery). Results of EEG recordings in the first 10 subjects will lead to continuation (presence of significant slow prefrontal oscillations during anxiety) or interruption (absence of signification oscillation) of the study.
Treatment: In vivo social exposure, EEG recording, Psychometric evaluation, and Visual Analogue Scale of anxiety
- Group 2.1Treatment being tested
In group 2.1, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after: 1. "real exposure": oral presentation to a panel of examiners 2. "virtual reality" : oral presentation to virtual examiners Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session. Psychometric evaluation will be performed prior to experimental sessions.
Treatment: In vivo social exposure, Social exposure in a virtual reality setting, EEG recording, Psychometric evaluation, and Visual Analogue Scale of anxiety
- Group 2.2Treatment being tested
In group 2.2, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after: 1. "virtual reality" : oral presentation to virtual examiners 2. "real exposure": oral presentation to a panel of examiners Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session. Psychometric evaluation will be performed prior to experimental sessions.
Treatment: In vivo social exposure, Social exposure in a virtual reality setting, EEG recording, Psychometric evaluation, and Visual Analogue Scale of anxiety
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Study of Slow Prefrontal Cortex Oscillations During Social Exposure in Social Anxiety Disorder
- Record updated
- 7 July 2026